A review on Tyrosine Kinase 2 inhibitors for the treatment of cancer

Abstract

Tyrosine kinase 2 (TYK2) encodes a signaling protein found in cells. TYK2 is being studied as a cancer treatment target due to its role in immune modulation and inflammation. Tyrosine kinase 2 inhibitors block tyrosine kinases, which are essential for cell proliferation, differentiation, and survival. TYK2 inhibitors have been thoroughly investigated for autoimmune diseases but recent development shows potency towards cancer treatments. This review is comprised of an updated compilation of TYK2 inhibitors that are available in the market for the treatment of cancer such as Deucravacitinib, Ruxolitinib, Fedratinib. And some are in the clinical phases such as Ropsacitinib and BMS-986202. However, the existing TYK2 inhibitors can cause resistance and adverse effects due to the. Therefore, more potent and selective inhibitors are needed to be developed. Lastly, this review discusses various approaches of discovering improved TYK2 inhibitors that can be used in the treatment of cancer.